Regeneron Extends $270M Deal to Supply Ebola Treatment Inmazeb

Regeneron Pharmaceuticals has extended its agreement with the US government to provide additional supplies of Inmazeb, an antibody-based treatment for Ebola disease. The expanded agreement with the Biomedical Advanced Research and Development Authority (BARDA) is worth approximately $270 million, with deliveries expected to continue through 2031.

Announced on October 26, 2026, the agreement builds on a procurement partnership that began in 2020. It aims to help maintain a ready supply of Inmazeb for the United States in case of future Ebola outbreaks.

Inmazeb is approved by the US Food and Drug Administration (FDA) to treat infections caused by Orthoebolavirus zairense, formerly known as Zaire ebolavirus. The treatment can be used in adults and children, including newborns whose mothers have the infection.

The medicine combines three monoclonal antibodies: atoltivimab, maftivimab and odesivimab. These antibodies work together to block the virus from entering cells and help the immune system target infected cells.

Inmazeb received FDA approval in 2020 and was the first treatment approved specifically for this type of Ebola infection. In a clinical trial, it reduced the risk of death by approximately 55% compared with an active control treatment among patients with low viral loads. The treatment has been administered to hundreds of patients since 2019.

Regeneron said the agreement reflects its continued collaboration with BARDA to ensure that medicines are available when an outbreak occurs. Maintaining emergency supplies is an important part of public health preparedness, as Ebola outbreaks can require rapid access to treatments and other medical resources.

Alongside the supply agreement, Regeneron is advancing research into maftivimab as a potential treatment for Bundibugyo virus disease. This is a separate type of Ebola disease caused by Bundibugyo virus, for which no treatment has been approved to date.

Maftivimab is one of the three antibodies in Inmazeb and has shown activity against Bundibugyo virus in laboratory studies and studies involving non-human primates. Based on these findings, the investigational antibody is being added to the PARTNERS clinical trial, which is evaluating potential treatments for Bundibugyo virus disease during the current outbreak in the Democratic Republic of the Congo.

The trial is coordinated internationally by the University of Oxford’s Pandemic Sciences Institute, led in the Democratic Republic of the Congo by the National Institute of Biomedical Research, and sponsored by the World Health Organization.

The additional Inmazeb supply agreement and the separate maftivimab research programme highlight Regeneron’s continued efforts to support Ebola preparedness. While Inmazeb is an approved treatment for infection caused by Orthoebolavirus zairense, maftivimab remains investigational for Bundibugyo virus disease and requires further clinical evaluation.